WEST LAFAYETTE, Ind., May 15, 2024 – On Target Laboratories, Inc., a privately held biotechnology company developing intraoperative molecular imaging agents to target and illuminate cancer during surgery, today announced the appointment of Dr. David Liu as part time Chief Medical Officer.
“We are delighted to welcome Dr. Liu to On Target Laboratories and look forward to the wealth of academic, clinical and commercial experience he will bring to this role,” said Ben Lundgren, Chief Executive Officer at On Target Laboratories. “Dr. Liu has been instrumental in establishing internationally utilized care pathways for cancer imaging, colorectal cancer, liver cancer and lung cancer. His unique perspective aligns perfectly with On Target’s current priorities and growth.”
Dr. Liu brings over twenty years of experience as a practicing Interventional Radiologist, and is an Associate Professor of Biomedical Engineering at the University of British Columbia with a voluntary Professorial Appointment with the University of Miami Miller School of Medicine. Dr. Liu will continue with his research and clinical practise while serving On Target Laboratories in this role.
“I am excited to join a team so passionately dedicated to enhancing patient care by illuminating cancer during surgery,” said Dr. Liu. “CYTALUX is a transformative technology, and I look forward to supporting its continued rollout with healthcare providers across the U.S.”
About Intraoperative Molecular Imaging
To date, there have been limited ways for surgeons to confidently assess the location and full extent of cancerous tissue while operating. Intraoperative Molecular Imaging (IMI) is an emerging category of technology for surgical oncology in which targeted imaging agents are injected into patients to highlight cancer cells making them visible during surgery.
About On Target Laboratories, Inc.
On Target Laboratories discovers and develops targeted intraoperative molecular imaging agents to illuminate cancer during surgery. Their molecular imaging technology, based on the pioneering work of Philip S. Low, PhD, Purdue University’s Presidential Scholar for Drug Discovery and the Ralph C. Corley Distinguished Professor of Chemistry, is comprised of a near-infrared dye and a targeting molecule, or ligand, that binds to receptors overexpressed on cancer cells. The imaging agents illuminate the cancerous tissue, which may enable surgeons to detect more cancer that otherwise may have been left behind.
CYTALUX, the company’s first product, received FDA approval of a New Drug Application for ovarian cancer in November 2021 and a supplemental New Drug Application for lung cancer in December 2022. CYTALUX targets the folate receptors commonly found on many cancers, binds to the cancerous tissue, and illuminates under near-infrared light. A single dose of the agent is administered via intravenous infusion prior to surgery and assists surgeons in visually identifying additional cancerous tissue to be removed during the operation. For more information visit www.ontargetlabs.com and www.cytalux.com.